Forbion mitigates risk by repeatedly backing the same successful management teams. After an exit, they often fund that team's next venture. This "founder recycling" strategy leverages proven operational chemistry and execution ability, as seen with the teams behind Gyroscope, IOLOS, and Ferdiva.

Forbion identified an arbitrage: promising biotech assets in China whose originators lacked global development expertise. Their strategy is to create new Western companies, in-license these assets, and install an experienced team to unlock their "rest of world" value, a model proven by a billion-dollar exit.

Mid-market PE firm Gryphon provides megafund-level capabilities with a 40-person operating team. This group uniquely combines former CEOs with functional experts in HR and finance, plus four PhD-level professionals in organizational development, to drive both performance and cultural growth in portfolio companies.

Ovelle's co-founders exemplify a common success pattern in biotech: one partner with profound scientific knowledge (Merrick) and another with extensive business experience (Travis). This combination covers critical aspects from research to capital raising and team building, as it's rare to find both skill sets in one person.

To prevent losing top scientific talent to administrative roles, the "Venture Catalyst" model pairs a scientist-founder with a dedicated business team. This allows the scientist to remain in the lab, focused on research, while the experienced partners handle finance, legal, and daily management.

A finance background in a science-heavy VC can be an asset. It forces a focus on translating complex science for investors and enables a higher-level perspective on portfolio construction. This helps avoid 'falling in love with the science' and prevents over-concentration in hot areas, ensuring a balanced fund.

Oshkosh's CVC team is a hybrid, not siloed in one department. It includes members from corporate development, a venture lead in a tech hub (Bay Area), and a counterpart in an engineering business unit. This structure ensures that strategic goals, technological feasibility, and market deal flow are constantly aligned.

A key skill in building a deep tech team is identifying individuals who can bridge the gap between complex science and business reality. These "translators" can articulate highly technical concepts in plain English, clarifying clinical relevance and commercial viability for decision-makers.

The biotech venture model is built on syndication, not competition. As a drug progresses, capital requirements balloon to hundreds of millions for late-stage trials, far exceeding any single VC's capacity. This structural reality forces firms to co-invest and partner throughout a company's lifecycle.